RISEDRONATE SODIUM

Search structure
Trade Names:
Synonyms:
Status: Approved (1998)
Entry Type: Small molecule
Molecule Category: Salt
UNII: OFG5EXG60L
Parent Compound:

Structure
InChI Key DRFDPXKCEWYIAW-UHFFFAOYSA-M
Smile O=P([O-])(O)C(O)(Cc1cccnc1)P(=O)(O)O.[Na+]
InChI
InChI=1S/C7H11NO7P2.Na/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);/q;+1/p-1

Physicochemical Descriptors

Property Name Value
Molecular Formula C7H10NNaO7P2
Molecular Weight 305.1
AlogP -0.37
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 5.0
Number of Rotational Bond 4.0
Polar Surface Area 148.18
Molecular species ACID
Aromatic Rings 1.0
Heavy Atoms 17.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Farnesyl diphosphate synthase inhibitor PubMed PubMed PubMed PubMed DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Osteoporosis 4 D010024 ClinicalTrials
Leukemia 3 D007938 ClinicalTrials
Osteogenesis Imperfecta 3 D010013 ClinicalTrials
Lymphoma 3 D008223 ClinicalTrials
Anorexia Nervosa 2 D000856 ClinicalTrials

Related Entries

UNKNOWN
Mixture

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Musculoskeletal and connective tissue disorders
25.59
Injury, poisoning and procedural complications
14.84
General disorders and administration site conditions
10.22
Gastrointestinal disorders
9.21
Nervous system disorders
5.76
Metabolism and nutrition disorders
3.68
Vascular disorders
3.38
Skin and subcutaneous tissue disorders
2.9
Respiratory, thoracic and mediastinal disorders
2.57
Cardiac disorders
2.52
Infections and infestations
2.45
Psychiatric disorders
2.35
Investigations
2.2
Immune system disorders
2.02

Cross References

Resources Reference
ChEBI 8868
ChEMBL CHEMBL1654
FDA SRS OFG5EXG60L
PubChem 4194514
SureChEMBL SCHEMBL18377
CONTENTS